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Abstract
Background: The change in renal function induced by first-line tyrosine kinase inhibitor therapy
for metastatic renal cell carcinoma remains unclear.
Methods: One hundred and thirty-four patients were evaluated. Sunitinib (SU) and sorafenib (SO)
were administered to 91 (67.9%) and 43 (32.1%) patients, respectively. The change in estimated glom-
erular filtration rate (ΔeGFR) was calculated as [(eGFR at each time point – pre-treatment eGFR)/pre-
treatment eGFR] × 100. ΔeGFR was compared between SU- and SO users using a mixed-effects model
for repeated measures data with two or greater. Additionally, predictors for ΔeGFR ≤ −10% at 6
months after therapy initiation were evaluated using multivariate logistic regression analysis.
Results: Throughout the 24 months after therapy initiation, ΔeGFR was negatively greater in SU
users, compared with that in SO users (P < 0.0001). In SU users, renal dysfunction was observed
regardless of pre-treatment chronic kidney disease (CKD) status, whereas the magnitude of renal
dysfunction was milder in SO users. In SO users without pre-treatment CKD, renal function did
not significantly deteriorate. Moreover, ΔeGFR ≤ −10% was more frequently observed in SU users
after 3 months (P = 0.0121) and 6 months (P = 0.0009). Finally, SU usage was an independent pre-
dictor for ΔeGFR ≤ −10% at 6 months (odds ratio 8.87, P = 0.0053), along with pre-treatment
hypertension (odds ratio 4.69, P = 00072).
Conclusions: Deterioration of renal function was stronger with SU than SO. During SU therapy,
renal function should be monitored and pre-treatment kidney function should be taken into con-
sideration for therapy selection.
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Introduction
The treatment for metastatic renal cell carcinoma (mRCC) is domi-
nated by molecular-targeted therapies. Presently, oncologists today
have a number of options to offer their patients. With the use of
these agents, the survival of patients can be extended. Vascular
endothelial growth factor (VEGF), one of the main angiogenic
growth factors, is a major therapeutic target for mRCC treatment
along with its downstream pathways and receptors. Sunitinib (SU)
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and sorafenib (SO) are orally administered inhibitors of tyrosine
kinases, including VEGF receptor (VEGFR) and platelet-derived
growth factor receptor. These receptor tyrosine kinases play a role
in the pathogenesis of clear-cell carcinoma, the predominant type of
renal cell carcinoma, through the involvement of the von Hippel-
Lindau gene (1–4). These novel drugs have contributed to an
improvement in prognosis for patients with mRCC compared with
previous treatments with cytokines (1,5).
VEGF inhibition causes a reduction in the free VEGF levels,
which may lead to endothelial dysfunction and glomerular epithelial
cell (podocyte) dysregulation, and ultimately resulting in clinical
adverse events, including renal dysfunction (6–9). However, the
kinetics of renal function during VEGFR-tyrosine kinase inhibitor
(TKI) therapy in real-world conditions remains unclear. Therefore,
we investigated the changes in renal function induced by first-line
TKI therapy, focusing on SU and SO, for mRCC.
Patients and methods
Between January 2007 and June 2016, 242 patients received first-line
SU (n = 123) and SO (n = 119) therapy for mRCC at our department.
Several patients were excluded because they had received prior treat-
ments with cytokines (n = 35), underwent hemodialysis or kidney
transplant (n = 32), or the administration period was too short (n =
15). From the remaining 160 patients, 26 patients with missing
detailed data were also excluded. Finally, 134 patients (SU: n = 91 and
SO: n = 43) were included in this analysis (Fig. 1).
All study procedures were approved by the Institutional Review
Board of Tokyo Women’s Medical University (ID: 4297), and were
in accordance with the Declaration of Helsinki.
Study design
The aim of this study was to evaluate the changes in renal function
during first-line SU and SO therapy, and to identify predictive factors
for the deterioration of renal function. The change in estimated glom-
erular filtration rate (ΔeGFR) was calculated as [(eGFR at each time
point – pre-treatment eGFR)/pre-treatment eGFR] × 100. ΔeGFR was
compared between patients that received SU and SO in the 134
included patients. Of these 134 patients, 38 patients were without pre-
treatment CKD, and 96 patients received pre-treatment CKD.
Moreover, ΔeGFR ≤ −10% was compared between patients who
received SU and SO at various time points, respectively (3, 6, 9 and 12
months after therapy initiation). Finally, we investigated the predictive
factors for ΔeGFR ≤ −10% at 6 months after therapy initiation.
Renal function
Renal function was assessed using eGFR, which was calculated
using the Modification of Diet in Renal Disease equation that was
recently modified for Japanese patients and is regulated by The
Japanese Society of Nephrology (10):
eGFR 194 serum creatinine age 0.739 if female ,1.094 0.287= × × × ( )
where eGFR is measured in ml/min/1.73m2, serum creatinine is in
mg/dl, and age in years.
Protocol for sunitinib and sorafenib therapy
Our protocol for SU and SO therapy has been described previously
(11–13).
For the SU regimen, we treated our patients with mRCC using a
4-week-on/2-week-off or a 2-week-on/1-week-off schedule. SU therapy
was initiated at a dose of 50mg/d, and was modified according to the
following three patient factors: (I) age >65 y, (II) serum creatinine levels
>2mg/dl and (III) body weight <50 kg. If one of these three factors
was noted, the initial dose was reduced to 37.5mg. If two factors were
noted, the initial dose was reduced to 25mg. The minimum initial dose
was 25mg, even if all three factors were noted. The dose was subse-
quently increased by 12.5mg based on the patient’s tolerance; how-
ever, the dose never exceeded 50mg. In the SO regimen, 200mg of SO
was orally administered twice daily and was increased up to 800mg
within 2–4 weeks in an effort to reduce adverse event development typ-
ically associated with a continuous dosing schedule. In these regimens,
the drugs were administered until disease progression was observed, or
intolerable adverse events developed.
Relative dose intensity
For SU, relative dose intensity (RDI) was determined after 6 months
(i.e. four cycles of SU) as the ratio of the cumulative dose received
during the cycle to 1400mg. For SO, RDI was defined as dose inten-
sity divided by the dose prescribed for the duration of the study ther-
apy (800mg × the number of days the patient received treatment).
Patient survival
To evaluate oncologic outcomes according to first-line therapy,
progression-free survival (PFS) and overall survival (OS) after ther-
apy initiation were analyzed. PFS and OS were defined as the time
from therapy initiation to the date of progression, and the date to
death from any cause, respectively.
Statistical analysis
Continuous variables were analyzed using the Mann–Whitney U-
test, and categorical variables were analyzed using the χ2 test.
ΔeGFR during therapy was compared between SU and SO users
using a mixed-effects model for repeated measures data for two or
greater. Multivariate logistic regression analysis was used to identify
predictors for the deterioration of renal function. Patient survival
was calculated using the Kaplan–Meier method and compared using
the log-rank test. Risk was expressed as odds ratios (ORs) and 95%
confidence intervals (CIs). All analyses were performed using JMP
®
13 (SAS Institute Inc., Cary, NC, USA), and P values <0.05 were
considered statistically significant.Figure 1. Study design.
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Results
Patient background
Table 1 shows the patients’ characteristics. Older age (P = 0.0436)
and poorer risk (P = 0.0399) according to the Memorial Sloan
Kettering Cancer Center (MSKCC) criteria were observed in patients
that received SU compared with those that received SO. There were
no differences in other factors including sex, prior nephrectomy sta-
tus, pathology, pre-treatment eGFR level, CKD status, urine protein
status, diabetes mellitus or hypertension status, and duration of
treatment or follow-up period (all P > 0.05).
Change in renal function with sunitinib vs. sorafenib
Figure 2 shows the comparison of ΔeGFR between SU and SO users
over the 24 months after therapy initiation in all 134 patients. The
mean ΔeGFR was negatively greater in SU users, compared with
that in SO users (P < 0.0001). Similar findings were observed in the
patients without pre-treatment CKD (P < 0.0001, Fig. 3) and those
with pre-treatment CKD (P = 0.0009, Fig. 4). According to the
CKD stage, there was no significant difference in ΔeGFR between
SU and SO users in the CKD 3a subgroup (n = 47, P = 0.100), as
shown in Supplementary Fig. 1, whereas ΔeGFR was negatively
greater in SU users, compared with SO users in the CKD 3b sub-
group (n = 39, P = 0.0202), as shown in Supplementary Fig. 2.
Deterioration of renal function with sunitinib vs.
sorafenib
Figure 5 shows the comparison of ΔeGFR ≤ −10% between patients
who received SU and those who received SO. Frequency of ΔeGFR ≤
−10% was significantly greater in patients that received SU, compared
with those that received SO at 3 months (32.5% vs. 10.8%, P =
0.0121) and 6 months (50.0% vs. 13.8%, P = 0.0009), respectively.
Predictors for deterioration of renal function
Table 2 shows the multiple logistic regression analysis for independ-
ent predictors for ΔeGFR ≤ −10% at 6 months after therapy initi-
ation in a cohort of 92 patients who received therapy for 6 months.
Overall, 36 patients (39.1%) had ΔeGFR ≤ −10%. Multivariate
analysis revealed that first-line SU therapy (ORs 14.0, P = 0.0016)
and pre-treatment hypertension (ORs 4.65, P = 0.0073) were inde-
pendent predictors after adjusting for other factors including age,
sex, RDI at 6 months, baseline serum eGFR level and pre-treatment
diabetes mellitus status.
Patient survival with sunitinib vs. sorafenib
During the follow-up period, disease progression (i.e. PFS) and
death from any cause (i.e. OS) were observed in 96 (71.6%) and 78
(58.2%) patients, respectively (Table 1). Figure 6 shows that there
Table 1. Patient background
Variable Sunitinib Sorafenib P
N = 91 N = 43
Sex 0.417
Male (ref. female) 66 (72.5%) 34 (79.1%)
Age, years 65.0 (60.0–71.0) 68.0 (63.0–74.0) 0.0436
Prior nephrectomy 0.903
With (ref. without) 79 (86.8%) 37 (86.1%)
Pathology 0.746
CCC 68 (74.7%) 31 (72.1%)
Non-CCC 23 (25.3%) 12 (27.9%)
CCC with spindle 7 (7.69%) 1 (2.33%)
Papillary renal cell carcinoma type 2 7 (7.69%) 4 (9.30%)
Others 4 (4.40%) 1 (2.33%)
Unknown 5 (5.49%) 6 (14.0%)
MSKCC 0.0399
Favorable 15 (16.5%) 6 (14.0%)
Intermediate 60 (65.9%) 36 (83.7%)
Poor 16 (17.6%) 1 (2.33%)
eGFR at treatment initiation, ml/min/1.73m2 49.4 (37.9–61.3) 51.7 (41.6–66.7) 0.0758
CKD at treatment initiation 0.741
With 66 (72.5%) 30 (69.8%)
Grade 3/4/5 59 (64.8%) /6 (6.59%)/1 (1.10%) 27 (62.8%)/2 (4.65%)/1 (2.33%)
Without 25 (27.5%) 13 (30.2%)
Urine protein at treatment initiation 0.347
With (ref. without) 26 (28.6%) 9 (20.9%)
Diabetes mellitus 0.639
With (ref. without) 14 (15.4%) 8 (18.6%)
Hypertension 0.800
With (ref. without) 36 (39.6%) 18 (41.9%)
Duration of treatment, months 9.17 (5.16–18.8) 7.69 (3.91–18.6) 0.678
Disease progression 63 (69.2%) 33 (76.7%) 0.368
Death from any cause 54 (59.3%) 24 (55.8%) 0.699
Duration of follow-up, months 19.7 (9.76–31.5) 15.5 (10.9–31.4) 0.834
Data are presented as frequency (percentage) or median (interquartile range), unless otherwise noted.
CCC; clear-cell carcinoma; MSKCC; Memorial Sloan Kettering Cancer Center; eGFR; estimated glomerular filtration rate; CKD; chronic kidney disease.
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was no significant difference in PFS nor OS between patients who
received SU and SO (median PFS: 10.6 vs. 11.6 months, P = 0.478;
OS: 24.4 vs. 22.8 months, P = 0.938). Additionally, similar findings
were observed in the 92 patients who received therapy for 6 months
(PFS: 14.7 vs. 15.7 months, P = 0.231; OS: 33.7 vs. 37.6 months,
P = 0.449) (Supplement Fig. 3).
Discussion
SU and SO have similar mechanisms of anti-carcinogenesis via
VEGFR-TKI, and the pharmacokinetics and pharmacodynamics are
also quite similar. Nevertheless, the present study revealed that SU
had a larger negative impact on renal function, compared with SO
during first-line TKI therapy for mRCC. Moreover, the deterior-
ation patterns were different between these two therapies; SU caused
a deterioration of renal function soon after therapy initiation and
the deterioration occurred regardless of pre-treatment renal function
(Figs 2–4). Meanwhile, SO did not have a negative effect on renal
function for approximately the first 9 months after therapy initi-
ation, and thereafter, renal dysfunction developed, especially in
patients with pre-treatment CKD (Figs 2 and 4). In addition, renal
function was not deteriorated by SO in patients without pre-
treatment CKD (Fig. 3). Finally, multivariate analysis showed that
SU usage was an independent predictor for renal dysfunction during
first-line therapy for mRCC. To the best of our knowledge, this is
the first study to demonstrate that SU has a larger negative impact
on sequential renal function than SO.
Figure 2. ΔeGFR by sunitinib and sorafenib therapy in 134 patients. Mean ΔeGFR was negatively greater in sunitinib users compared with that in sorafenib users
throughout the study (P < 0.0001). Error bars indicate standard deviation. P value was obtained using a mixed model test of trend profile. ΔeGFR, change in esti-
mated glomerular filtration rate.
Figure 3. ΔeGFR by sunitinib and sorafenib therapy in 38 patients without pre-treatment chronic kidney disease. Mean ΔeGFR was negatively greater in sunitinib
users compared with that in sorafenib users throughout the study (P < 0.0001).
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SU-induced renal dysfunction has been reported in previous stud-
ies. Motzer et al. reported that 66/375 (17.6%) patients experienced
all-grade creatinine increase during SU therapy for mRCC (1), and
Zhu et al. reported in a meta-analysis that the incidence of all-grade
creatinine increase was 65.6% in patients that received SU therapy
(14). We have previously reported that SU therapy was associated
with deceased eGFR; the median relative change in eGFR from base-
line to the nadir was −21% (9). Meanwhile, Miyake et al. reported
no change in renal function during first-line targeted therapy (15).
The differences in findings might be caused by different study designs,
as several types of agents were analyzed together. Unlike SU, studies
evaluating SO’s impact on renal function are limited. SO is considered
a safer targeted agent for tolerability (16–18). In this context, we
found that the toxicity of SO on renal function was milder, compared
with that of SU, especially in patients without CKD (Fig. 3).
Interestingly, among patients with pre-treatment CKD, the magnitude
of ΔeGFR difference between the two drugs was higher in the CKD
3b subgroup compared with the CKD 3a subgroup that was caused
by severer deterioration of renal function from SU therapy in the
CKD 3b subgroup (Supplementary Figs 1 and 2). Thus, even though
impairment of renal function was observed during SU therapy regard-
less of pre-treatment CKD status, patients with severe renal insuffi-
ciency might need to be more carefully monitored during SU therapy.
Moreover, the magnitude of ΔeGFR induced by SU was higher in
patients without pre-treatment CKD compared with those with CKD
3a (Fig. 3 and Supplementary Fig. 1). This finding was consist with a
previous study by Khan et al. who suggested that a stronger decline
of creatinine clearance was observed in patients with de novo renal
insufficiency (i.e. without baseline CKD) compared with those with
baseline renal insufficiency during SU or SO therapy (19).
Figure 4. ΔeGFR by sunitinib and sorafenib therapy in 96 patients with pre-treatment chronic kidney disease. Mean ΔeGFR was negatively greater in sunitinib
users compared with that in sorafenib users throughout the study (P = 0.0009).
Figure 5. Renal function deterioration with sunitinib vs. sorafenib therapy.
The number of patients with ΔeGFR ≤ −10% was significantly higher in suni-
tinib users compared with that in sorafenib users at 3 and 6 months after
therapy initiation (3m: 32.5% vs. 10.8% P = 0.0121; 6m: 50.0% vs. 13.8% P =
0.0009). The number of sunitinib users evaluated after 3, 6, 9 and 12 months
was 27, 31, 24 and 25, respectively, and the number of sorafenib users was
13, 19, 18 and 16, respectively.
NS, not significant.
Table 2. Multivariate logistic regression analysis for the predictors
of ΔeGFR ≤ −10% at 6 months after first-line therapy in a cohort of
92 patients who received first-line therapy for 6 months
Variable Multivariate
ORs (95% CI)
P
*Age 0.98 (0.92–1.04) 0.480
Sex 0.788
Male (ref. female) 1.19 (0.34–4.17)
Therapy 0.0016
Sunitinib (ref.sorafenib) 14.0 (2.72–72.5)
*RDI during 6 months 0.98 (0.94–1.02) 0.317
*Baseline serum eGFR level 1.03 (0.99–1.06) 0.150
Diabetes mellitus 0.0712
With (ref. without) 4.00 (0.89–18.1)
Hypertension 0.0073
With (ref. without) 4.65 (1.51–14.3)
*Continuous variable.
ORs, odds ratio; CI, confidence interval; RDI, relative dose intensity;
eGFR, estimated glomerular filtration rate.
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Fukuda et al. reported that patients treated for a long time
tended to have greater eGFR deterioration (9). In another study,
there was a significant association between the deterioration of renal
function and treatment duration (15). Thus, as the analysis targeting
renal function could be affected by treatment duration, we evaluated
the value of renal dysfunction at a fixed time-point (i.e. at 6 months
after therapy initiation). Moreover, since we believed that not only
duration but also intensity of therapy could influence renal function,
RDI was incorporated into the multivariate analysis (Table 2).
Consequently, SU usage was an independent factor after exclusion
of possible bias induced by these confounders.
Although renal function has been suggested as an ‘on-target’
adverse event induced by TKI in several studies, the evidence
remains unclear (9,20). Previously, we reported that renal dysfunc-
tion induced by SU had an association with better prognosis (9).
Another study indicated that presence of proteinuria, and not renal
insufficiency, was correlated with poorer PFS (20). In this context,
our analysis did not show that oncologic outcome was associated
with differences of deterioration of renal function between SU and
SO (Fig. 6 and Supplement Fig. 3).
It is difficult to adequately explain the different findings for these
two VEGFR-TKI drugs. The loss of VEGF function through pharma-
cologic inhibition is associated with damage to glomerular endothelial
cells and podocytes. Additionally, anti-VEGF treatment leads to vaso-
constriction via decreased nitrogen monoxide and prostaglandin I2
production, resulting in decreased blood flow in the glomeruli (7,21).
SU and SO target a number of kinases, such as VEGFRs or platelet-
derived growth factor receptors; they are not selective. Although these
two drugs have similar pharmacokinetics/pharmacodynamics charac-
teristics, including mechanism of action, metabolism and elimination
(22), SU inhibits a wider range of tyrosine kinases (23,24). Thus, SU
might have a potentially stronger influence on the deterioration of
renal function; however, this is merely speculation.
Our study is limited by its retrospective design and a small number
of patients. Patients with poor performance status or other patient-
related backgrounds could influence the physician’s treatment plan;
thus, unmeasured or immeasurable confounders might have affected
our findings. Therefore, our findings should be confirmed in a larger
prospective randomized controlled trial. Additionally, as shown in
Table 1, patients that received SO were older, and had a trend towards
better baseline renal function, which may have affected the results.
Though possible confounders were adjusted through multivariate ana-
lyses, patient background should be matched in further studies.
In conclusion, SU and SO can deteriorate renal function during
first-line therapy for mRCC; however, the magnitude of deterior-
ation was higher in SU users. Renal dysfunction was observed,
regardless of pre-treatment renal function in SU users, whereas renal
function was not significantly deteriorated by SO, especially in
patients without pre-treatment CKD. Consequently, renal function
should be monitored during SU therapy, as well as in patients with
pre-treatment CKD during SO therapy. We believe that these find-
ings will be helpful for decisions on treatment strategies for first-line
VEGFR-TKI therapy for mRCC.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical
Oncology online.
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